Home
Medical News
Lastet 10 Medical News
U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
FDA approves Inlyta to treat patients with a type of advanced kidney cancer
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
FDA. New and Generic Drug Approvals - January 27, 2012
FDA. New and Generic Drug Approvals - January 26, 2012
FDA. New and Generic Drug Approvals - January 25, 2012
FDA. New and Generic Drug Approvals - January 24, 2012
FDA. New and Generic Drug Approvals - January 23, 2012
FDA. New and Generic Drug Approvals - January 20, 2012
Dictionary
Browse alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
W
V
Y
Z
Drugs A-Z
Browse alphabetically Medicines Human:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Orfan Drugs
Browse alphabetically Supplements:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Wiew Veterinary medicines:
All Veterinary medicines
Health articles
Choose category
Herbal Articles
Toxic Substances A-Z Index
Parasitic Diseases
Mendeleev periodic table
Pharmaceutical companies
Medicinal plants list
EU Drugs
Cosmetics
Be eco! Be organic!
List of Vitamins
List of Minerals
Active substances and excipients
Medical Tests. Diagnostics
Health Organizations
Symptoms and signs of disease
List of Diseases
Drug manufacturers
Choose country
UK
Canada
USA
Denmark
Greece
Norway
Poland
Portugal
Germany
France
Japan
Brazil
Sweden
Italy
Spain
China
Argentina
Czech Republic
Hospitals Worldwide
Choose country
Australia
Brazil
Canada
India
Ireland
Israel
Malaysia
Mexico
Netherlands
Nigeria
Saudi Arabia
South Africa
Spain
Switzerland
USA
UK
Search drugs:
Home
-
Drugs and Supplements A-Z
Drugs and Sepplements. Supplements E
Eye-Vites, Nature`s Bounty
Eyebright & L-Lutein, G&G Vitamins
Eyebright (Euphrasia officinalis), Solgar
Eyebright 430 mg, Bronson Laboratories
Eyebright 470 mg, Puritan`s Pride
Eyebright 470 mg, Vitamin World
Eyebright 550 mg, HealthAid
Eyebright Bayberry Supreme, Gaia Herbs
Eyebright Formula, Nature`s Way
Eyebright Herb, Gaia Herbs
Eyebright Herb, Nature`s Way
Eyebright Herb, NOW Foods
Eyebright Herbal Liquids, HealthAid
Eyebright Liquid Herbal Extract, Herb Pharm
Eyebright Nettle Compound, Herb Pharm
Eyebright Plus (Tincture), Nutri-West
Eyebright Tincture, St. Francis Herb Farm Incorporated
Eyebright, Natura Laboratory
Eyebright, Natures Formulae Health Products
Eyebright, Nature`s Herbs
EyeCare, Healthy America
Eyes Bright, Futurebiotics LLC
Eyes-Bright Remedy, Spectrum Herbal
Eyesight Rx Vision Health, Physician Formulas
EyeVit, HealthAid
Eyewise, Nature`s Best UK
EZ Breathe, Strauss Herb Co
EZ Cleanse, Vitamin Research Products
EZ Flex, Metagenics
Ez Gest, Shaklee Canada
EZ Lung, E-Z QUIT
EZ QUIT Cleanser, E-Z QUIT
EZ Sit Drops, Strauss Herb Co
EZ Trim, EZTrim Products
EZ-Breather Lung System, Susan Ambrosino`s Herb Club
EZ-Go, Doctor`s Choice, Naturally
EzAir capsule, Wei Laboratories
Ezerex, Atlas Operations
EZEyes, Chrysantis
EZorb Capsules, Elixir Industry
Previous
1
2
...
47
48
49
50
51
52
53
54
55
Next
General Search
Latest News
U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
FDA approves Inlyta to treat patients with a type of advanced kidney cancer
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
FDA. New and Generic Drug Approvals - January 27, 2012
Latest Drugs
Efavirenz Teva
Desloratadine Actavis
Repaglinide Accord
Emselex
Hepsera
Zulvac 1 Ovis
Zulvac 1 Bovis
Levetiracetam Sun
Inovelon
Olanzapine Glenmark Europe
Last medical tags:
Torisel
,
temsirolimus
,
Inlyta
,
chronic myeloid leukemia
,
bosutinib
,
Inlyta
,
renal cell carcinoma
,
kidney cancer
,
myelin
,
Tysabri
,
natalizumab
,
brain infection
,
progressive multifocal leukoencephalopathy
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
thoracic aortic transection
,
endovascular graft
,
methotrexate
,
Voraxaze
,
cancer chemotherapy drug
,
glucarpidase
,
Adcetris
,
bleomycin
,
multifocal leukoencephalopathy
,
CardioGen-82
,
radiation
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
FDA
,
New drugs approval 2012
,
drugs approved by FDA
,
raltegravir
,
Isentress
,
antiretroviral medicines
,
Theravance
,
Relovair
,
asthma
,
fluticasone
,
bronchitis
,
neuromuscular disease
,
SMA
,
muscle atrophy
,
Resolor
,
prokinetic
,
prucalopride
,
ADHD
,
psychiatric behavioural disorder
,
Venvanse
,
lisdexamfetamine dimesylate
,
type 2 diabetes mellitus
,
Actoplus Met XR
,
pioglitazone
,
Mylan
,
Eprosartan Mesylate Tablets
,
Teveten
,
antimicrobials
,
cephapirin
,
cephalosporin
,
teriflunomide
,
Rebif
,
alanine aminotransferase levels
,
flu-like symptoms
,
multiple sclerosis
,
electrical pulses
,
implantable pulse generator
,
Precision Plus Spinal Cord Stimulator
,
genetic blood clotting disorder
,
hemophilia A
,
Advate
,
bleeding episodes
,
heart failure
,
heart transplantation
,
Pediatric Medical Device Safety
,
pulsatile cardiac assist device
,
selective serotonin reuptake inhibitor
,
SSRI
,
pulmonary hypertension
,
» All tags
Sitemap